Sabine D. Brookman-May: MA supports EFS as a surrogate for OS in Muscle invasive bladder cancer after neoadjuvant treatment
Sabine D. Brookman-May shared a post on X:
”This MA supports Event-free survival as a surrogate for Overall survival in MIBC after neoadjuvant treatment.
Strong association of Event-free survival + Overall survival for treatment effects (R2 0.94) + survival outcome
Significant association between 1 year Event-free survival/3 year Overall survival, 3 year Event-free survival/5 year Overall survival, median Event-free survival/Overall survival Bladder Cancer ”
Source: Sabine D. Brookman-May/X
Sabine D. Brookman-May is the Vice President of Bladder Cancer Development, Research and Development at Janssen Pharmaceutical Companies of Johnson & Johnson. She also serves as a professor of Urology at Ludwig Maximilian University of Munich, specializing in Urology, Oncology, and Sports and Exercise Medicine.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023